Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series

By Coutinho Rita   Costa Dolors   Carrió Ana   Muñoz Concha   Vidal Ana   Belkaid Mohammed   Campo Elias   Nomdedeu Benet  

Annals of Hematology, Vol. 89, Iss. 10, 2010-10 ,pp. : 1069-1070

Springer Publishing Company

Access to resources Recommend Favorite

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

By Wijermans P.   Lübbert M.   Verhoef G.   Klimek V.   Bosly A.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 9-17

Springer Publishing Company

Access to resources Recommend Favorite

A limited number of 5-azacitidine cycles can be effective treatment in MDS

By Müller-Thomas Catharina   Schuster Tibor   Peschel Christian   Götze Katharina  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 213-219

Springer Publishing Company

Access to resources Recommend Favorite

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

By Götze Katharina   Platzbecker Uwe   Giagounidis Aristoteles   Haase Detlef   Lübbert Michael   Aul Carlo   Ganser Arnold   Germing Ulrich   Hofmann Wolf-Karsten  

Annals of Hematology, Vol. 89, Iss. 9, 2010-09 ,pp. : 841-850

Springer Publishing Company

Access to resources Recommend Favorite

Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment

By Moon Joon   Kim Shi   Kang Byung   Chae Yee   Kim Jong   Baek Jin   Park Jae   Song Moo   Chung Joo   Won Jong   Lee Sang   Joo Young   Kim Yeo   Kim Hyeong   Jo Deog   Sohn Sang  

Annals of Hematology, Vol. 89, Iss. 7, 2010-07 ,pp. : 681-689

Springer Publishing Company

Access to resources Recommend Favorite